New drug shows promise in slowing devastating ALS progression
NCT ID NCT01492686
Summary
This study tested whether a drug called MCI-186 could help people with ALS (amyotrophic lateral sclerosis) maintain their ability to perform daily activities. Researchers gave 137 ALS patients either the drug or a placebo through daily IV infusions for 24 weeks to see if it slowed disease progression. The main goal was to measure changes in patients' physical function and quality of life while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Osaka, Japan
Conditions
Explore the condition pages connected to this study.